Open offers highest since 2008 as acquisition, takeover attempts surge

Most open offers are for a minimum of an additional stake of 26 per cent and allow public shareholders an exit after the acquisition

mergers & acquisitions, mergers, acquisitions
Open offers surged to a 17-year high in 2025, with 121 takeover-triggered bids as private equity and strategic buyers chased control in Indian companies. | Illustration: Binay Sinha
Sachin P Mampatta Mumbai
4 min read Last Updated : Dec 21 2025 | 11:54 PM IST
Open offers this calendar year, following attempts at acquisition and takeover, came in at more than two a week. 
There were 121 such open offers to acquire additional shares following a substantial acquisition or change of control, shows the data compiled by primedatabase.com. 
This is the highest in 17 years and the second-highest since 1997 (the data is available since that year). The previous high was in 2008, which saw 133 open offers. 
In terms of value, the offer — of ₹41,443.95 crore this year — is the third-highest on record, with 2013 (₹47,473.77 crore) and 2022 (45,649.39 crore) being the only other two years with higher numbers. 
Takeover provisions are triggered when certain conditions are met. This broadly includes entities acquiring more than a 5 per cent stake in a company in a year, acquiring 25 per cent overall, or if there is a change in control in the company. 
Most open offers are for a minimum of an additional stake of 26 per cent and allow public shareholders an exit after the acquisition.
 
Exiting shareholders usually get a price related to the acquisition price or the volume-weighted price of the company’s shares over a period ranging from 60 days to 52 weeks, based on the circumstances around the acquisition. 
The largest open offers this year include Torrent Pharmaceuticals’ for JB Chemicals & Pharmaceuticals (₹6,842.80 crore), private-equity player CVC Capital’s Aquilo House’s for housing finance company Aavas Financiers (₹3,682.15 crore), and multinational IHH Healthcare’s acquisition of Fortis Healthcare (₹3,349.44 crore). 
“Mergers and acquisitions pick up when the economy is doing well,” said Pranav Haldea, managing director, Prime Database. 
Private-equity firms are more active than they were a few years ago and are looking for controlling stakes, which may be driving some of the acquisitions, Haldea added. 
This is happening at a time when there is a generational transition taking place in many businesses. 
When the next generation is not interested in the family business, promoters often look for other options such as selling out to another company in the same sector or to private-equity investors, he said. 
Private-equity transactions in November touched their highest level since 2022, according to Grant Thornton Bharat’s Dealtracker. 
There was a record number of mergers and acquisitions (99) with a shift being towards strategic, lower-value deals, according to the Grant Thornton report.
 
Profitable private-equity investment in India in the next era requires operational changes and deep involvement, which can largely happen only with majority or control stakes, noted Sumat Chopra, partner, Kearney, and head, private equity and merger and acquisition practice.
 
A lot of promoters who have seen their business grow significantly in the past few years are willing to bring in private-equity investors who can professionalise and scale up the business. This is driving a surge in transactions, initially led by technology firms and those in financial services, though this may change.   
 
“I expect the industrials and manufacturing sectors to see a big uptick,” said Chopra, adding that health care, consumer and renewable energy were also likely to see increased acquisitions in the time to come.
 
The average acquired amount as a share of the offer amount was 91 per cent in 2008. It is 31 per cent this year so far.  It can take many months for the open offer to be completed, which may also affect the final acquired amount. For example, a company that enters an open offer in October may not immediately be able to deploy the offer amount.
 
A pricing mismatch where shareholders were expecting a higher price than has been decided upon for the open offer could also be a reason for lower acquired amounts, according to Haldea. 
 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Open offersTorrent PharmaceuticalsFortis Healthcare

Next Story